REGENTIS BIOMATERIALS LTD.

Regentis Biomaterials develops regenerative medicine solutions focused on tissue repair and regeneration. The company's primary platform is Gelrin, a hydrogel matrix composed of polyethylene glycol diacrylate and denatured fibrinogen designed to treat damaged or diseased tissue across multiple therapeutic areas. The company also markets GelrinC, a cell-free, off-the-shelf hydrogel formulation currently in Phase II clinical trials for cartilage injuries in the knee.

The company operates primarily in the United States market, with its technology platform targeting orthopedic and tissue repair applications. Regentis was incorporated in 2004 and is headquartered in Herzliya, Israel. The company is publicly listed on the NYSE. Specific information regarding employee count, revenue scale, and detailed segment breakdowns is not available from the provided data. The company operates within the medical instruments and supplies sector, specifically in orthopedic and surgical appliances.